Allotment of 44,000 Equity Shares to Non-Promoter Allottees pursuant to conversion of 14,667 Warrants into Equity Shares, consequent to the 1:2 Bonus Issue.

Date: 23rd October, 2026 BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street - Fort, Mumbai — 400 001. Ref.: BSE Scrip Code - 539730 Subject: Outcome of Board Meeting Dated 23rd October, 2026 Re: Allotment of 44,000 Equity Shares to Non-Promoter Allottees pursuant to conversion of 14,667 Warrants into Equity Shares, consequent to the 1:2 Bonus Issue. Dear Sir, This is to inform you that Board of Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on October 22, 2025, had allotted convertible warrants on preferential basis to Allottees on December 29, 2025 allotted convertible warrants on a preferential basis to the respective allottees. Further, we would like to inform you that the Warrant Holders have paid the balance of the consideration and have applied for exercising their rights for conversion of 14,667 warrants into 44,000 number of Equity Shares. Consequently, the Board of Directors in its meeting held on October 23, 2026 has allotted 44,000 Equity Shares of face value Rs. 10/- each to the warrant holder as per following details: Sr. Name of Allottee Category Total Number of Number of After No. of Investor number of Equity Shares Warrants effect of convertible allotted upon Outstanding Bonus warrants conversion of for issue in allotted on Warrants on Conversion Ratio December October 23, 1:2 29, 2025 2026# 1 DIVYA Non- 8,000 2667 0 8000 AGGARWAL Promoter 2 INDU Non- 8,000 8000 0 24,000 RAMANLAL Promoter GOLECHA 3 SAHIL DHIR Non- 4,000 4000 0 12,000 Promoter TOTAL 20,000 14,667 0 44,000 #After the Company’s 1:2 Bonus Issue, the entitlement on outstanding warrants is proportionately adjusted, giving each warrant the right to the increased number of equity shares with the exercise price revised accordingly. The allotment of the equity shares shall be made in dematerialized form and the equity shares so allotted shall rank pari passu with the existing Equity Shares of the Company in all respects. The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular dated January 30, 2026 are enclosed as “Annexure The meeting commenced at 03:00 p.m. and concluded at 05:45 p.m. Kindly take the aforesaid information on your records. Thanking you, FOR FREDUN PHARMACEUTICALS LIMITED FREDUN NARIMAN MEDHORA MANAGING DIRECTOR DIN NO.: 01745348 Encl. : Annexure I Annexure I Information as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Issuance of Securities: Sr. Particulars of Securities Details of Securities a) Type of securities proposed to be Equity Shares upon conversion of Warrants into Equity issued Shares of Rs. 10/- each. b) Type of issuance Preferential Issue in accordance with Chapter V of the SEBI ICDR Regulations 2018 and other applicable law. c) Total number of securities Allotment of 44,000 proposed to be issued or the total amount for which the securities Fully Paid-Up Equity Shares. will be issued In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s): i. Name of Investors Mentioned in the Covering Letter above. ii. Post Allotment of securities - Warrants were allotted on December 29, 2025, carrying outcome of the subscription, the right to subscribe to Equity Shares upon exercise of issue price / allotted price (in the option attached to each warrant, at an issue price of case of convertibles), Rs. 1,250/- per warrant, of which Rs. 312.50/- per warrant, being 25% of the issue price, was payable upfront. Subsequently, pursuant to the 1:2 Bonus Issue made by the Company, the entitlement attached to the outstanding warrants was adjusted in accordance with the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Accordingly, pursuant to such adjustment, 14,667 outstanding warrants were exercisable into 44,000 Equity Shares, i.e. three Equity Shares for each outstanding warrant, upon payment of the applicable balance consideration. iii. No. of Investors 3 (Three) iv. In case of convertibles - As the total consideration of the 14,667 Convertible intimation on conversion of Warrants is received, the Equity Shares are allotted securities or on lapse of the pursuant to exercise of the conversion of Convertible tenure of the instrument; Warrants. v. Any cancellation or termination Not Applicable of proposal for issuance of securities including reasons thereof.